Personalized therapy in COPD, are we there yet?
A webinar with expert speakers Marc Miravitlles and Arschang Valipour
Tuesday, 26th November'19
1.00-2.00 PM
In English
Among other topics, the webinar will cover...
- The benefits that patients derive from dual bronchodilation
- The convenience of ICS-containing treatments in COPD
- How can blood eosinophil count guide us in treatment decisions
Meet the experts
Arschang Valipour
Arschang Valipour is the Head of the Department of Respiratory and Critical Care Medicine at the Hospital North in Vienna.
He is licensed in Internal and Pulmonary Medicine, Intensive Care Medicine and General Medicine.
Prof. Valipour further founded the Karl-Landsteiner-Institute of Lung Research and Respiratory Oncology and contributes as an Associate Editor of Respiration and the International Journal of COPD, and reviewer for several scientific journals.
Marc Miravitlles
Marc Miravitlles is a pulmonologist at the Hospital Universitari Vall d’Hebron in Barcelona, Spain.
His primary research activities include COPD, alpha-1-antitrypsin deficiency, lung defence mechanisms, and respiratory infections.
Dr. Miravitlles served as the Secretary of the Spanish Society of Pneumology and Thoracic Surgery (1999 – 2003), and the responsible for International Relationships (2006 – 2012).
He was the Chair of the Respiratory Infections Group of the ERS (2008 – 2011), and the Guidelines Director of the ERS (2015 – 2018).
He acts as a consultant for the development of ATS and ERS guidelines of COPD, exacerbations of COPD and management of alpha-1 antitrypsin deficiency.
Dr. Miravitlles is a consultant of the Spanish Ministry of Health for the development of the National Strategy Against COPD (2009 to present), and from 2012 he is the coordinator of the Spanish National Guidelines for COPD.
